» Articles » PMID: 16251302

Mechanisms of Azole Resistance in a Clinical Isolate of Candida Tropicalis

Overview
Specialty Pharmacology
Date 2005 Oct 28
PMID 16251302
Citations 61
Authors
Affiliations
Soon will be listed here.
Abstract

Azole resistance has been insufficiently investigated in the yeast Candida tropicalis. Here we determined the molecular mechanisms responsible for azole resistance in a clinical isolate of this pathogenic yeast. Antifungal susceptibility testing performed by a disk diffusion method showed resistance or markedly decreased susceptibility to azoles, which was confirmed by determination of MICs. Considering the relationship between azole susceptibility and the respiration reported for other yeast species, the respiratory activity of this isolate was investigated. Flow cytometry using rhodamine 123 and oxygraphy demonstrated an increased respiratory activity, which was not linked to an overexpression or increased number of copies of the mitochondrial genome. Among previously described resistance mechanisms, an increased activity of efflux pumps was investigated by flow cytometry using rhodamine 6G. However, the efflux of rhodamine 6G was lower in the resistant isolate than in susceptible ones. Likewise, real-time reverse transcription-PCR quantification of the expression of C. tropicalis MDR1 (CtMDR1), which encodes an efflux protein belonging to the major facilitator superfamily, did not show overexpression of this gene. In contrast, the resistant isolate overexpressed the CtERG11 gene coding for lanosterol 14alpha-demethylase. This was in agreement with the larger amount of ergosterol found in this isolate. Moreover, sequencing of CtERG11 showed a point mutation leading to a tyrosine substitution in the protein sequence, which might lead to decreased binding affinity for azoles. In conclusion, overexpression of CtERG11 associated with a missense mutation in this gene seemed to be responsible for the acquired azole resistance of this clinical isolate.

Citing Articles

Brazilian Green Propolis Extract-Loaded Poly(Ε-Caprolactone) Nanoparticles Coated with Hyaluronic Acid: Antifungal Activity in a Murine Model of Vulvovaginal Candidiasis.

Dos Reis Teixeira A, De Vasconcelos Quaresma A, Branquinho R, De Oliveira P, Garcia Suarez J, Brandao G AAPS PharmSciTech. 2025; 26(3):86.

PMID: 40087194 DOI: 10.1208/s12249-025-03081-z.


Geraniol Potentiates the Effect of Fluconazole against Planktonic and Sessile Cells of Azole-Resistant : In Vitro and In Vivo Analyses.

Silva-Rodrigues G, Castro I, Borges P, Suzukawa H, Souza J, Bartolomeu-Goncalves G Pharmaceutics. 2024; 16(8).

PMID: 39204397 PMC: 11360560. DOI: 10.3390/pharmaceutics16081053.


Role of ERG11 and MDR1 genes in cycloheximide and multidrug resistance in Candida species.

Huma Z, Saleem S, Imran M, Raza S, Jabeen K, Arshad F Braz J Microbiol. 2024; 55(3):2569-2579.

PMID: 38980650 PMC: 11405649. DOI: 10.1007/s42770-024-01436-5.


Spectrum of activity and mechanisms of azole-bisphosphonate synergy in pathogenic .

Kane A, Dinh H, Campbell L, Cain A, Hibbs D, Carter D Microbiol Spectr. 2024; 12(6):e0012124.

PMID: 38695556 PMC: 11237636. DOI: 10.1128/spectrum.00121-24.


Antifungal resistance, combinations and pipeline: oh my!.

Stover K, Hawkins B, Keck J, Barber K, Cretella D Drugs Context. 2023; 12.

PMID: 38021410 PMC: 10653594. DOI: 10.7573/dic.2023-7-1.


References
1.
Servouse M, Karst F . Regulation of early enzymes of ergosterol biosynthesis in Saccharomyces cerevisiae. Biochem J. 1986; 240(2):541-7. PMC: 1147448. DOI: 10.1042/bj2400541. View

2.
Tortorano A, Rigoni A, Biraghi E, Prigitano A, Viviani M . The European Confederation of Medical Mycology (ECMM) survey of candidaemia in Italy: antifungal susceptibility patterns of 261 non-albicans Candida isolates from blood. J Antimicrob Chemother. 2003; 52(4):679-82. DOI: 10.1093/jac/dkg393. View

3.
Price M, Larocco M, Gentry L . Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period. Antimicrob Agents Chemother. 1994; 38(6):1422-4. PMC: 188224. DOI: 10.1128/AAC.38.6.1422. View

4.
Wingard J . Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis. 1995; 20(1):115-25. DOI: 10.1093/clinids/20.1.115. View

5.
Marichal P, Vanden Bossche H, Odds F, Nobels G, Warnock D, Timmerman V . Molecular biological characterization of an azole-resistant Candida glabrata isolate. Antimicrob Agents Chemother. 1997; 41(10):2229-37. PMC: 164098. DOI: 10.1128/AAC.41.10.2229. View